GeoVax Labs, Inc. (NASDAQ:GOVX) Short Interest Down 12.3% in March

GeoVax Labs, Inc. (NASDAQ:GOVX) was the target of a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 610,600 shares, a decrease of 12.3% from the February 28th total of 696,400 shares. Approximately 6.9% of the company’s shares are sold short. Based on an average daily trading volume, of 678,200 shares, the short-interest ratio is presently 0.9 days.

Institutional Trading of GeoVax Labs

Several institutional investors have recently made changes to their positions in GOVX. Geode Capital Management LLC raised its position in shares of GeoVax Labs by 59.0% in the 4th quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock worth $223,000 after buying an additional 33,440 shares during the period. Citadel Advisors LLC acquired a new stake in GeoVax Labs during the fourth quarter worth about $104,000. Virtu Financial LLC acquired a new stake in GeoVax Labs during the third quarter worth about $97,000. Finally, Northern Trust Corp purchased a new position in shares of GeoVax Labs in the 4th quarter worth about $29,000. 6.09% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, D. Boral Capital reaffirmed a “buy” rating and issued a $18.00 target price on shares of GeoVax Labs in a research note on Friday, March 28th. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $14.20.

GeoVax Labs Price Performance

NASDAQ GOVX opened at $1.08 on Wednesday. The company has a market cap of $10.19 million, a P/E ratio of -0.19 and a beta of 3.06. GeoVax Labs has a 12 month low of $1.03 and a 12 month high of $11.18. The company has a 50-day moving average of $1.62 and a 200-day moving average of $2.10.

GeoVax Labs (NASDAQ:GOVX) last released its earnings results on Thursday, March 27th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.49. The company had revenue of $3.00 million during the quarter, compared to analysts’ expectations of $2.38 million. As a group, equities research analysts anticipate that GeoVax Labs will post -4.49 EPS for the current year.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.